How has Mirum Pharmaceuticals, Inc.'s non-cash interest expense changed year-over-year?

Mirum Pharmaceuticals, Inc.'s non-cash interest expense increased by 4.8% year-over-year, from $433K to $454K.

Mirum Pharmaceuticals, Inc. MIRM Non-cash interest expense

BridgeBio PharmaBBIO

——

Revenue$159.9M+43.3%

Operating income-$789.5M-5,100%

Net income-$790.2M-5,284%

EPS (diluted)-$13.43-4,377%

Cash & equivalents$261.5M+43.5%

Total debt$13.5M+56.4%

Total equity$242.5M+4.0%

Total assets$890.9M+29.1%

Operating cash flow-$228.8M-11,566%

CapEx$664.0K+1,520%

Free cash flow-$229.4M-11,360%

Market cap$6.53B+152%

Enterprise value$6.28B+162%

P/S11.5×+4.6×

Operating margin-139.8%-168pp

Net margin-140.2%-169pp

FCF margin-30.3%—

Return on equity-335.8%-377pp

Debt / equity0.1×0.0×

Current ratio2.1×-1.1×

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Mirum Pharmaceuticals, Inc.'s non-cash interest expense?: Mirum Pharmaceuticals, Inc. (MIRM) reported non-cash interest expense of $454K in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s non-cash interest expense changed year-over-year?: Mirum Pharmaceuticals, Inc.'s non-cash interest expense increased by 4.8% year-over-year, from $433K to $454K.